1. Search Result
Search Result
Isoforms Recommended: CA
Results for "

hCA VII

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-W074975

    5-Amino-1,3,4-thiadiazole-2-sulfonamide

    Carbonic Anhydrase Cancer
    CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is a selective inhibitor of carbonic anhydrase B (HCA-B) and isoforms I, II, IV, and VII. CL 5343 has a Ki of 7.9 nM for hCA II. CL 5343 acts as a CA9 ligand to achieve targeted delivery of maytansine to the cell membrane of SKRC52 renal cancer cells. CL 5343 is useful in the development of therapeutics for diseases associated with CA overactivity, such as glaucoma, epilepsy, and cancer .
    CL 5343
  • HY-178362

    Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII/VII-IN-1 is an orally active hCA II (KI = 12.3 nM), and hCA VII (KI = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .
    CAII/VII-IN-1
  • HY-149329

    Carbonic Anhydrase Neurological Disease Cancer
    hCAIX/VII-IN-1 is a selective hCA VII/IX inhibitor. hCAIX/VII-IN-1 inhibit hCAⅠ, hCAⅡ, hCAⅣ, hCAⅦ and hCAⅨ with Ki values of 336.2 nM,185.8 nM, 1055 nM, 35.6 nM and 28.0 nM, respectively. hCAIX/VII-IN-1 can be used for the research of cancer and neurological diseases .
    hCAIX/VII-IN-1
  • HY-172816

    Carbonic Anhydrase mTOR NKCC Neurological Disease
    Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels .
    Carbonic anhydrase inhibitor 32
  • HY-148135

    Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and >50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-132156

    Carbonic Anhydrase Neurological Disease
    Carbonic anhydrase inhibitor 22 (Compd 2g), a sulfonamide carbonic anhydrase inhibitor, with Ki values of 762 nM (hCA I), 20.3 nM (hCA II), 8.3 nM (hCA VII), 17.9 nM (hCA IX) and 10.5 nM (hCA XII), repectively .
    Carbonic anhydrase inhibitor 22
  • HY-169163

    Carbonic Anhydrase Cholinesterase (ChE) Neurological Disease
    hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .
    BChE-IN-36
  • HY-175441

    Carbonic Anhydrase Cardiovascular Disease Neurological Disease Cancer
    Carbonic anhydrase activator 1 (Compound 17) is an orally active and a BBB-penetrable Carbonic anhydrase (CA) activator with KAs of 7.8, 3.9  and 2.1 μM for hCA I, hCA VA and hCA VII. Carbonic anhydrase activator 1 can be used for cancers, glaucoma, cardiovascular diseases and neurodegenerative disorders like epilepsy research .
    Carbonic anhydrase activator 1
  • HY-182070

    Carbonic Anhydrase Cancer
    Carbonic anhydrase-IN-38 (compound 5c) is a carbonic anhydrase inhibitor with antiproliferative activity, with Ki values of 576.2 nM, 41.3 nM and 86.9 nM against hCA VII, hCA IX and hCA XII, respectively. Carbonic anhydrase-IN-38 can be used in research related to triple-negative breast cancer and glioblastoma .
    Carbonic anhydrase-IN-38
  • HY-180056

    Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .
    CAII-IN-12

オンラインお問い合わせ

入力情報は安全に管理されます. 必須入力項目.

タイトル

 

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

 

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: